Patient-perceived effectiveness and impact on quality of life of solifenacin in combination with an α-blocker in men with overactive bladder in Sweden: a non-interventional study

Abstract

Treating male lower urinary tract symptoms (LUTS) by targeting the prostate would have limited effect on overactive bladder (OAB) symptoms. This study assessed perceived symptoms and quality of life (QoL) of male patients with OAB treated with an α-blocker plus solifenacin in daily clinical practice. Male patients aged ≥40 years were included after the decision was made to initiate treatment with an α-blocker for LUTS plus solifenacin for OAB symptoms. The primary endpoint was change in patient perception of bladder condition (PPBC) questionnaire score over 6 months. Other assessments included the OAB-questionnaire short form (OAB-q SF) and International Prostate Symptom Score (IPSS). Interpretation of the study data was hindered by not meeting the enrollment target and a high dropout rate. In 36 evaluable patients, mean (SD) PPBC score improved from 4.3 (0.93) at baseline ("moderate" to "severe" problems) to 3.5 (1.06) at month 6 ("minor" to "moderate" problems). OAB-q SF scores and total IPSS also improved. In this patient population, treatment with solifenacin and an α-blocker resulted in improvements in male patient perception of their LUTS and QoL, although the results should be interpreted with caution due to the low number of patients with complete data.

The relevance of studying the state of blood circulation of the neurogenic bladder in children

“…Альфаадреноблокаторы показали свою эффективность в различных аспектах коррекции нейрогенных расстройств мочевого пузыря. Так, в определенных клинических ситуациях терапия адреноблокаторами может привести к таким результатам, как уменьшение степени пузырномочеточникового рефлюкса (ПМР), улучшение со стороны императивного недержания, более редкие обострения инфекций мочевыводящих путей, выраженное улучшение уродинамических показателей, уменьшение или устранение остаточной мочи [21][22][23][24].…”

Effects of Tamsulosin Combined With Solifenacin on Lower Urinary Tract Symptoms: Evidence From a Systematic Review, Meta-Analysis, and Trial Sequential Analysis of Randomized Controlled Trials

“…It has been suggested that M3 receptors on the bladder detrusor muscle might be the target of this drug (Chen et al, 2010). Through inhibiting and blocking the binding of acetylcholine to the M3 receptor, reducing the contractile force of the detrusor, and inhibiting contraction of the detrusor, solifenacin can improve the symptoms of frequent urination and urgency (Henningsohn et al, 2017). However, due to the wide distribution of M3 receptors in the body, adverse reactions such as dry mouth, blurred vision, and constipation may occur.…”